IP Library Granted Patent US 11,230,715
Granted Patent B2
US 11,230,715 · App. 16/857,803 · Granted Jan 25, 2022

Composition for delivery of genetic material

Inventors: Yiqi Seow (Singapore, SG); Lydia Alvarez (London, GB); Matthew Wood (Oxford, GB)
Assignee: Oxford University Innovation Limited
C12N15/113A61K47/42A61K47/6901A61K48/0025C07K7/06C07K14/005C07K14/435C07K14/705C12N15/111A61K48/00C07K2319/035C12N2310/14C12N2310/315C12N2320/32C12N2760/20022C12N2760/20031
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,230,715
App. No.
16/857,803
Granted
Jan 25, 2022
Kind
B2
Abstract

The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

Claims (10)

1. A pharmaceutical composition comprising exosomes comprising exogenous genetic material transfected into the exosome by a transfection reagent, wherein the exogenous genetic material is a therapeutic exogenous plasmid comprising a therapeutic gene operatively linked to a regulatory sequence.

2. The pharmaceutical composition according to claim 1 , wherein the exosomes comprise a targeting moiety expressed on the surface of the exosome.

3. The pharmaceutical composition according to claim 2 , wherein the targeting moiety targets the exosome to the brain, liver, pancreas, lung or muscle tissue or neuronal tissue.

4. The pharmaceutical composition according to claim 2 , wherein the exosomes comprise an exosomal transmembrane protein which has been modified to incorporate the targeting moiety.

5. The pharmaceutical composition according to claim 1 , wherein the exogenous plasmid is an open circular plasmid.

6. The pharmaceutical composition according to claim 1 , wherein the exogenous plasmid is a super coiled plasmid.

7. The pharmaceutical composition according to claim 1 , wherein the therapeutic gene replaces a non-functional gene.

8. The pharmaceutical composition according to claim 1 , wherein the therapeutic gene neutralizes a disease-causing mutation.

9. The pharmaceutical composition according to claim 1 , wherein the therapeutic exogenous plasmid further comprises a signal peptide sequence.

10. An exosome comprising a therapeutic exogenous plasmid, wherein the therapeutic exogenous plasmid comprises a therapeutic gene operatively linked to a regulatory sequence.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2020
From: SEOW, YIQI; ALVAREZ, LYDIA; WOOD, MATTHEW
To: ISIS INNOVATION LIMITED
Reel/Frame 052491/0860 →
CHANGE OF NAME Recorded Apr 24, 2020
From: ISIS INNOVATION LIMITED
To: OXFORD UNIVERSITY INNOVATION LIMITED
Reel/Frame 052491/0919 →
Priority Claims (2)
GB 0906692 · Apr 17, 2009 · national
GB 0906693 · Apr 17, 2009 · national
Continuity (4)
Continuation 16264257 · Jan 31, 2019
Continuation 14847853 · Sep 8, 2015
Continuation 13264485
Related Publication 20200308587A1 · Oct 1, 2020